Difference between revisions of "Vandetanib (Caprelsa)"
m |
m (→References) |
||
| Line 31: | Line 31: | ||
[[Category:RET inhibitors]] | [[Category:RET inhibitors]] | ||
[[Category:SRC inhibitors]] | [[Category:SRC inhibitors]] | ||
| + | [[Category:TEK inhibitors]] | ||
[[Category:VEGF inhibitors]] | [[Category:VEGF inhibitors]] | ||
Revision as of 17:00, 14 August 2015
General information
Class/mechanism: Tyrosine kinase inhibitor of EGFR (epidermal growth factor receptor), VEGF (vascular endothelial cell growth factor), RET (rearranged during transfection), BRK (breast tumor kinase/protein tyrosine kinase 6), TIE2, EPH, Src. Inhibits angiogenesis, endothelial cell migration, and tumor growth.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Vandetanib (Caprelsa) package insert PDF pages 6-8[5]
- Vandetanib (Caprelsa) patient drug information (UpToDate)[6]
History of changes in FDA indication
- 4/6/2011: Initial FDA approval "for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease."
Also known as
Zactima, ZD6474.
References
- ↑ 1.0 1.1 Vandetanib (Caprelsa) package insert
- ↑ Vandetanib (Caprelsa) package insert (locally hosted backup)
- ↑ Caprelsa manufacturer's website
- ↑ Caprelsa Risk Evaluation and Mitigation Strategy (REMS) Program
- ↑ Vandetanib (Caprelsa) package insert PDF pages 6-8
- ↑ Vandetanib (Caprelsa) patient drug information (UpToDate)